Psoriasis Biologics Show Varied Risk of Hidradenitis Suppurativa

The risk of developing hidradenitis suppurativa (HS) as a side effect of biologic treatments for psoriasis differs significantly depending on the specific class of biologic agent used, according to an analysis of a large clinical database. This analysis revealed that the likelihood of treatment-induced HS varied by more than twofold across different types of biologic therapies. Specifically, the study identified that tumor necrosis factor (TNF) inhibitors were associated with a higher incidence of paradoxical HS compared to other biologic classes. Paradoxical HS refers to the development of a new condition or exacerbation of a pre-existing one as a direct result of a medical treatment, in this case, biologics prescribed for psoriasis. Psoriasis is a chronic autoimmune disease that causes raised, red, scaly patches on the skin, while HS is a chronic inflammatory skin condition characterized by painful lumps, abscesses, and scarring, typically in areas with sweat glands. The study's findings suggest that clinicians should be aware of this differential risk when selecting biologic agents for patients with psoriasis, particularly those with a history or predisposition to HS. The precise mechanisms underlying the development of paradoxical HS in response to biologics are not fully understood but may involve complex interactions with the immune system and inflammatory pathways. TNF inhibitors, a common class of biologics used to treat moderate to severe psoriasis, work by blocking the action of TNF-alpha, a key cytokine involved in inflammation. However, this broad immunosuppressive effect might also disrupt other immune responses, potentially leading to the onset of HS in susceptible individuals. Other biologic classes, such as interleukin (IL) inhibitors (e.g., IL-17, IL-23, IL-12/23 inhibitors), have shown varying associations with HS development, with some appearing to carry a lower risk than TNF inhibitors. The database analysis likely included a substantial number of patients, providing robust statistical power to detect these differences. The researchers emphasized the importance of patient counseling regarding potential side effects and the need for vigilant monitoring for any new dermatological symptoms during biologic therapy. This information is crucial for optimizing treatment strategies and minimizing adverse events in the management of psoriasis, a condition that affects millions worldwide. Further research may be warranted to elucidate the specific immunological pathways involved and to develop predictive models for identifying patients at higher risk of paradoxical HS.